|
1
|
Dabigatran versus warfarin in patients with atrial fibrillation.
|
N Engl J Med
|
2009
|
39.97
|
|
2
|
Telmisartan, ramipril, or both in patients at high risk for vascular events.
|
N Engl J Med
|
2008
|
19.76
|
|
3
|
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
|
Lancet
|
2008
|
13.34
|
|
4
|
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial.
|
Lancet
|
2008
|
13.15
|
|
5
|
Homocysteine lowering with folic acid and B vitamins in vascular disease.
|
N Engl J Med
|
2006
|
11.72
|
|
6
|
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
|
N Engl J Med
|
2009
|
11.49
|
|
7
|
Basal insulin and cardiovascular and other outcomes in dysglycemia.
|
N Engl J Med
|
2012
|
10.09
|
|
8
|
Effect of ramipril on the incidence of diabetes.
|
N Engl J Med
|
2006
|
9.69
|
|
9
|
Randomized trial of primary PCI with or without routine manual thrombectomy.
|
N Engl J Med
|
2015
|
7.83
|
|
10
|
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.
|
JAMA
|
2005
|
7.35
|
|
11
|
Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial.
|
JAMA
|
2005
|
6.68
|
|
12
|
Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis.
|
N Engl J Med
|
2014
|
6.65
|
|
13
|
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.
|
Lancet
|
2010
|
6.31
|
|
14
|
Aspirin in patients undergoing noncardiac surgery.
|
N Engl J Med
|
2014
|
6.10
|
|
15
|
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
|
N Engl J Med
|
2010
|
6.05
|
|
16
|
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.
|
JAMA
|
2006
|
5.74
|
|
17
|
Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy.
|
N Engl J Med
|
2015
|
5.31
|
|
18
|
Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
|
N Engl J Med
|
2006
|
5.24
|
|
19
|
Use of ramipril in preventing stroke: double blind randomised trial.
|
BMJ
|
2002
|
4.91
|
|
20
|
Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies.
|
Eur Heart J
|
2007
|
4.88
|
|
21
|
Effects of off-pump and on-pump coronary-artery bypass grafting at 1 year.
|
N Engl J Med
|
2013
|
4.27
|
|
22
|
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
|
N Engl J Med
|
2007
|
3.74
|
|
23
|
Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.
|
Lancet
|
2006
|
3.43
|
|
24
|
Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.
|
Circulation
|
2006
|
3.38
|
|
25
|
Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range.
|
Circulation
|
2008
|
2.98
|
|
26
|
Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study.
|
Ann Intern Med
|
2011
|
2.80
|
|
27
|
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study.
|
J Hypertens
|
2009
|
2.68
|
|
28
|
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
|
Circulation
|
2013
|
2.64
|
|
29
|
Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study.
|
Circulation
|
2013
|
2.48
|
|
30
|
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
|
Am Heart J
|
2004
|
2.25
|
|
31
|
Clonidine in patients undergoing noncardiac surgery.
|
N Engl J Med
|
2014
|
2.07
|
|
32
|
Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).
|
Stroke
|
2008
|
2.06
|
|
33
|
Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study.
|
Circulation
|
2003
|
1.98
|
|
34
|
Effect of telmisartan on renal outcomes: a randomized trial.
|
Ann Intern Med
|
2009
|
1.85
|
|
35
|
Irbesartan in patients with atrial fibrillation.
|
N Engl J Med
|
2011
|
1.84
|
|
36
|
Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review.
|
Lancet
|
2002
|
1.79
|
|
37
|
Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy.
|
J Am Coll Cardiol
|
2007
|
1.76
|
|
38
|
Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study.
|
Am Heart J
|
2007
|
1.69
|
|
39
|
Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation.
|
Circulation
|
2010
|
1.68
|
|
40
|
Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial.
|
JAMA
|
2010
|
1.66
|
|
41
|
Relationship of anti-60 kDa heat shock protein and anti-cholesterol antibodies to cardiovascular events.
|
Circulation
|
2002
|
1.65
|
|
42
|
Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease.
|
Am Heart J
|
2005
|
1.65
|
|
43
|
Two-year outcomes in patients admitted with non-ST elevation acute coronary syndrome: results of the OASIS registry 1 and 2.
|
Indian Heart J
|
2005
|
1.59
|
|
44
|
Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.
|
Ann Intern Med
|
2011
|
1.56
|
|
45
|
Challenges of establishing new antithrombotic therapies in atrial fibrillation.
|
Circulation
|
2007
|
1.52
|
|
46
|
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study.
|
Eur Heart J
|
2008
|
1.52
|
|
47
|
Nitrous oxide and serious morbidity and mortality in the POISE trial.
|
Anesth Analg
|
2013
|
1.50
|
|
48
|
Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension.
|
Circulation
|
2005
|
1.47
|
|
49
|
Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients.
|
Eur Heart J
|
2007
|
1.46
|
|
50
|
Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W.
|
Eur Heart J
|
2010
|
1.45
|
|
51
|
Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy.
|
Diabetes Care
|
2002
|
1.40
|
|
52
|
Effect of angiotensin-converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction--a meta-analysis.
|
Eur J Heart Fail
|
2005
|
1.40
|
|
53
|
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).
|
J Am Coll Cardiol
|
2012
|
1.28
|
|
54
|
Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study.
|
Circulation
|
2003
|
1.27
|
|
55
|
The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes.
|
Diabetes Care
|
2004
|
1.18
|
|
56
|
Prognostic utility and characterization of cell-free DNA in patients with severe sepsis.
|
Crit Care
|
2012
|
1.18
|
|
57
|
Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
|
Am Heart J
|
2010
|
1.11
|
|
58
|
Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
|
Lancet Neurol
|
2010
|
1.10
|
|
59
|
Rationale and design of the Investigation of the Management of Pericarditis (IMPI) trial: a 2 × 2 factorial randomized double-blind multicenter trial of adjunctive prednisolone and Mycobacterium w immunotherapy in tuberculous pericarditis.
|
Am Heart J
|
2012
|
0.99
|
|
60
|
The Family Atherosclerosis Monitoring In earLY life (FAMILY) study: rationale, design, and baseline data of a study examining the early determinants of atherosclerosis.
|
Am Heart J
|
2009
|
0.98
|
|
61
|
Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study.
|
Kidney Int
|
2004
|
0.98
|
|
62
|
Cognitive function and anticoagulation control in patients with atrial fibrillation.
|
Circ Cardiovasc Qual Outcomes
|
2010
|
0.96
|
|
63
|
Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.
|
Circulation
|
2003
|
0.90
|
|
64
|
Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.
|
Circulation
|
2004
|
0.88
|
|
65
|
Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients.
|
Eur J Cardiovasc Prev Rehabil
|
2003
|
0.87
|
|
66
|
Steroids In caRdiac Surgery (SIRS) trial: acute kidney injury substudy protocol of an international randomised controlled trial.
|
BMJ Open
|
2014
|
0.83
|
|
67
|
ACE inhibition in stable coronary artery disease.
|
N Engl J Med
|
2005
|
0.82
|
|
68
|
Referrals in acute coronary events for CARdiac catheterization: The RACE CAR trial.
|
Can J Cardiol
|
2010
|
0.81
|
|
69
|
Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure.
|
Eur J Heart Fail
|
2014
|
0.79
|
|
70
|
Canadian-led capacity-building in biostatistics and methodology in cardiovascular and diabetes trials: the CANNeCTIN Biostatistics and Methodological Innovation Working Group.
|
Trials
|
2011
|
0.79
|
|
71
|
Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors.
|
Am J Cardiovasc Drugs
|
2002
|
0.78
|
|
72
|
The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.
|
Nat Clin Pract Cardiovasc Med
|
2008
|
0.76
|
|
73
|
Reevaluation by high-performance liquid chromatography: clinical significance of microalbuminuria in individuals at high risk of cardiovascular disease in the Heart Outcomes Prevention Evaluation (HOPE) Study.
|
Am J Kidney Dis
|
2006
|
0.76
|
|
74
|
Impact of ramipril on the circadian periodicity of acute myocardial infarction.
|
Am J Cardiol
|
2006
|
0.75
|
|
75
|
Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux.
|
Am Heart J
|
2010
|
0.75
|
|
76
|
Predictors, Prognosis, and Management of New Clinically Important Atrial Fibrillation After Noncardiac Surgery: A Prospective Cohort Study.
|
Anesth Analg
|
2017
|
0.75
|